Initiated 2026-10-17 · Price $18.66 (as of 2026-10-16, stockanalysis.com) · Mkt cap $21.9bn (1,172.4mm diluted shares) · Health care / generic and established-brand pharmaceuticals · Model: verified

Rating: Buy — Conviction: High

Viatris trades at ~7x forward earnings and a ~9% free-cash-flow yield as though its five-year revenue decline will continue. The 2026 data say otherwise: guidance was raised, Q2 revenue grew 4% operationally, and a $600–700mm cost program is landing. Even with the company's growth targets haircut and the exit multiple below today's, the cash flows support more than the current price. The risk is that the decline returns, through generic price erosion or another India plant failure, and the debt then works against the equity.

Conviction tests (3a-v-c): T1 pass (Buy at both ±1pp: Base +27% at +1pp, +75% at −1pp) · T2 pass (exit-multiple DCF alone +19%, Gordon alone +76%) · T3 pass · T4 pass (no pending deal, ruling or single-product event worth >25%; Q3 print 2026-11-05 and meloxicam PDUFA 2026-12-27 are routine)

The rule gives High. I would personally sit nearer Medium: management has called restructuring "one-time" every year since 2021, and the model's EBITDA excludes those costs after 2026 apart from what capex carries.

Model value range vs price
Bear $12.18Base $27.55Bull $44.47Price $18.66

Business overview

Viatris sells off-patent branded drugs (Lipitor, Norvasc, Viagra, EpiPen; brands $9.18bn of FY2025 net sales) and generics ($5.07bn) in 165+ markets. FY2025 sales by segment: Developed Markets $8.51bn (60%), Greater China $2.33bn (16%), Emerging Markets $2.21bn (16%), JANZ $1.19bn (8%). Most revenue is outside the US. Three variables drive earnings. The first is the rate of generic and established-brand price erosion against volume and new launches (guided at $450–550mm of new-product revenue in 2026). The second is the supply reliability of the India manufacturing network: an FDA warning letter at Indore cost ~$370mm of FY2025 revenue, and Nashik had a February fire and a May Form 483. The third is the cost program, which reaches $600–700mm when fully implemented, with up to $250mm reinvested.

Competition

In US generics the main rival is Teva, with a 6.1% share of US generic prescriptions (TTM to Q2 2026). Teva's generics excluding Revlimid fell 2% globally in Q2 2026, and it guides flat to down low single digits for 2026. Sandoz's generics grew 1% at constant currency in Q2 2026, with its growth coming from biosimilars. The read-across is that generic pricing is stable but not improving, so Viatris's 2026 growth comes from Greater China (+16% operational in Q2) and new products, not from base generics. Competitive pressure would show up first as price, in US generic tenders and China volume-based procurement. The closest listed comparables sit on both sides of Viatris: Organon (7.1x aggregator EV/EBITDA) and Perrigo (8.8x) are valued as low-growth carve-outs, while Teva (14.4x) has earned a growth multiple from its branded pivot.

Bull case

  1. Growth reset holds — China and new brands carry revenue at the company's base 3–4% CAGR through 2030, or 5–6% with selatogrel, cenerimod and business development. Plays out if Greater China keeps growing double digits and new-product revenue compounds past $500mm. Model: rev_growth
  2. Cost program lands in full — $600–700mm of savings lifts margin toward 32% by 2030. Plays out if reinvestment stays below $250mm and India remediation finishes in 2027. Model: ebitda_margin
  3. Re-rating on proven growth — two to three years of positive revenue and gross leverage held at 2.8–3.2x earns a 9.5x exit and 2.5% terminal growth. Plays out if the pipeline (meloxicam PDUFA December 2026; selatogrel and cenerimod Phase 3) delivers. Model: exit_ev_ebitda, terminal_growth

Bear case

  1. Erosion and plant quality return the decline — revenue falls back to its −1% to −2% pre-2026 trend, and remediation spend persists. Plays out if Nashik or Indore escalate to import alerts, or if US and China pricing tightens. Model: rev_growth, capex_pct_rev
  2. Margin squeeze — EM and China mix, reinvestment and erosion outrun savings, so margin drifts to ~26.5%. Plays out if adjusted EBITDA growth trails revenue in 2027. Model: ebitda_margin
  3. Leverage magnifies the downside — $13.4bn of debt against a $21.9bn market cap and an S&P BB+ rating. A higher risk premium (8.5% WACC) and a 6.5x exit compress the equity. Plays out if gross leverage moves back above 3.2x. Model: wacc, exit_ev_ebitda

Valuation & balance sheet

Metric (definition) Current Own history (range or 5y avg) Peers Source, as-of
EV/EBITDA, model basis (EV $34.3bn = mkt cap $21.9bn − cash $0.9bn + debt $13.4bn; EBITDA = adj. EBITDA less SBC) 8.62x FY2025; ~8.1x 2026 guide EBITDA margin 32.0% / 30.7% / 27.8% FY2023–25 TEVA 14.4x · AMRX 13.6x · PRGO 8.8x · OGN 7.1x (aggregator TTM, lease-inclusive) model-inputs.json; stockanalysis.com 2026-10-16
Forward P/E (consensus) 7.3x n/a (unverified) TEVA 14.7x · AMRX 19.1x · PRGO 7.3x · OGN 3.9x stockanalysis.com 2026-10-16
FCF yield (aggregator TTM) / dividend yield 9.1% / 2.6% FY2025 FCF $1.94bn ($2.2bn ex transaction costs) FCF: TEVA 2.8% · AMRX 1.2% · PRGO 5.2% · OGN 15.7% stockanalysis.com 2026-10-16; Q4 2025 release

Model-implied value range (from model-summary.json; generic module, Gordon-growth DCF and exit-EV/EBITDA DCF, midpoints): Bear $12.18 · Base $27.55 · Bull $44.47 per share, i.e. implied returns of −34.7% / +47.6% / +138.3% vs $18.66. These ranges show how the bull and bear drivers translate into value; they are not price targets.

Balance sheet: net leverage 3.1x model-basis FY2025 EBITDA (gross 3.4x; the company reports 2.9x gross on adjusted EBITDA, against a 2.8–3.2x target), coverage 8.3x, liquidity $0.9bn cash at 2026-06-30 plus ~$380mm Biocon proceeds received in July. The nearest material maturity is $1.74bn of current debt within 12 months. Ratings: S&P BB+ stable (downgraded February 2025), Fitch BBB stable (affirmed April 2026), Moody's n/a (unverified).

Model note: tier full, status built, verification verified (3,207 formula cells matched in LibreOffice). No unverified inputs. No assumptions without basis. Scenario consistency OK on all 14 rows.

Relative value vs peers
MetricVTRSTEVAOGNAMRXPRGOPeer medianvs median
P/E (TTM)n/a69.0x17.4x39.9xn/a39.9x
P/E (forward)7.3x14.7x3.9x19.1x7.2x11.0x−33%
PEG2.5x2.0x2.3x2.1xn/a2.1x+19%
EV/EBITDA (TTM)7.8x14.4x7.1x13.6x8.8x11.2x−30%
EV/Sales (TTM)2.3x3.6x1.8x3.0x1.3x2.4x−5%
P/B1.5x6.2x3.6xn/a0.9x3.6x−58%
FCF yield9.1%2.8%15.7%1.2%5.2%4.0%+5.1pp
Dividend yield2.6%0.0%0.6%0.0%7.0%0.3%+2.3pp
P/E (TTM)TEVA69.0xAMRX39.9xOGN17.4x
P/E (forward)AMRX19.1xTEVA14.7xVTRS7.3xPRGO7.2xOGN3.9x
PEGVTRS2.5xOGN2.3xAMRX2.1xTEVA2.0x
EV/EBITDA (TTM)TEVA14.4xAMRX13.6xPRGO8.8xVTRS7.8xOGN7.1x
EV/Sales (TTM)TEVA3.6xAMRX3.0xVTRS2.3xOGN1.8xPRGO1.3x
P/BTEVA6.2xOGN3.6xVTRS1.5xPRGO0.9x
FCF yieldOGN15.7%VTRS9.1%PRGO5.2%TEVA2.8%AMRX1.2%
Dividend yieldPRGO7.0%VTRS2.6%OGN0.6%TEVA0.0%AMRX0.0%

As of 2026-10-17. One source and one definition for every company: aggregator TTM and consensus-forward multiples, lease-inclusive EV. Not the model's own EV basis (see the report's valuation table). All figures at the 2026-10-16 close, fetched 2026-10-17 (Saturday). Dashed line = peer median. Source: stockanalysis.com /stocks/<ticker>/statistics/, fetched 2026-10-17.

Notes. Viatris and Perrigo have negative trailing GAAP earnings (Viatris: FY2025 goodwill impairment), shown as n/a by the source. PEG as given by the source, resting on its consensus growth estimates; the source shows none for Perrigo. Amneal's P/B is 185.46x (above the 100x display cap) on near-zero book equity. Teva and Amneal pay no dividend (0).

Scenario stress test

Reasoned from the bull/bear drivers above. The model column comes from the scenario overlays (Base case + shock).

Scenario Effect Mechanism Magnitude Model Δ value vs Base ($/sh)
S1 Fast equity crash − Levered equity stub de-rates in a liquidity sell-off despite defensive demand Med −$2.26
S2 Slow bear / recession − EM demand, payer pressure and pricing soften while prescriptions hold. Transitory, so much milder than the bear case's permanent decline Med −$2.51
S3 Rapid rate shock − Higher discount rate on a levered value stock; $1.7bn of near-term maturities refinance higher High −$4.25
S4 Slow rate grind − Grinding discount-rate and refinancing drag Med −$2.05
S5 Soft-landing cuts + Lower rates re-rate a levered value stock High +$3.59
S6 Recession-driven cuts ± Rate relief offset by EM and pricing softness and risk-off de-rating Low +$0.78
S7a Credit liquidity shock − Crossover-rated issuer: spreads gap wider and the equity is sold Med −$1.98
S7b Slow default cycle − Crossover credit pays more to refinance; customers aren't credit-sensitive Med −$2.05
S8 Stagflation − Tender and procurement prices can't follow input, wage and freight costs Med −$2.44
S9a Dollar spike − Majority of sales outside the US translate lower Low −$0.99
S9b Dollar slide + Translation tailwind (FX added ~1.5pp in Q2 2026) Low +$0.99
S10 Melt-up − Rotation out of low-multiple defensives into momentum Low −$0.85
S11 Energy supply shock − Freight, solvent and API input costs Low −$0.07
S12 Mega-cap/AI derating + Rotation into cheap defensive value Low +$1.13

Currently active/on watch per the playbook: S3 partially active (price-level leg only); S8, S10 and S11 on watch.

Model value change vs Base, by scenario
S3 Rapid rate shock−$4.25S2 Slow bear / recession−$2.51S8 Stagflation−$2.44S1 Fast equity crash−$2.26S4 Slow rate grind−$2.05S7b Slow default cycle−$2.05S7a Credit liquidity shock−$1.98S9a Dollar spike−$0.99S10 Melt-up−$0.85S11 Energy supply shock−$0.07S6 Recession-driven cuts+$0.78S9b Dollar slide+$0.99S12 Mega-cap/AI derating+$1.13S5 Soft-landing cuts+$3.59

What would change the call

Upgrades if: 2027 guidance shows operational revenue growth of ≥3% and EBITDA growth ahead of revenue, and restructuring cash costs fall below $300mm. Downgrades if: operational revenue turns negative again for two quarters, Nashik or Indore receives an import alert or a new warning letter, or gross leverage exceeds 3.2x.

Watch items

Sources